From the Press
Dr. Daphna Laifenfeld Speaks at PMWC 2022
Genetika+ personalizes treatment in the mental health space, initially focusing on depression. The Genetika+ platform uses innovative technology to predict the best drug treatment for each patient, enabling faster treatment, fewer side effects, and lower dosing.
Female Led Genetika+ Grew and Gained Funding Through MassChallenge
How did a female-led startup from the MC18 Israel cohort turn their MassChallenge experience into a $10 million Series A funding round? Learn more about Genetika+ and its co-founders, Talia Cohen Solal and Daphna Laifenfeld, in our most recent case study.
Genetika+ CEO Talia Cohen Solal Brings Precision Medicine to Brain Health
Depression, historically, has been treated by trial and error until a therapy with a positive and stable outcome can be identified. Genetika+ is changing that with precision, personalized testing that enables the right antidepressant to be selected for patients the first time.
Combating Depression
A successful female entrepreneur, Talia Cohen Solal is an extremely driven, compassionate, and curious individual. As the CEO & Co-Founder of Genetika+, a biotech start-up specialized in developing new tools for personalized medicine in major depression, she is advancing treatment in a much-needed space. In this interview, she speaks on a range of topics – from a unique scientific approach to depression treatment, to her journey from academic to entrepreneur, from challenges faced in the industry, to her passion for entrepreneurship. Here are some excerpts from the interview.
Discover 5 Top Healthcare Startups tackling Depression
Staying ahead of the technology curve means strengthening your competitive advantage. That is why we give you data-driven innovation insights into the healthcare sector. This time, you get to discover 5 hand-picked startups tackling depression and mental health.